Key Points for Decision Makers {#FPar1}
==============================

This 3-year observational study shows that healthcare costs of patients with chronic kidney disease (CKD) not receiving dialysis are, on average, €2.7k.The last stages of CKD account for 17--22% of unit healthcare costs of patients receiving dialysis. Policymakers should enhance all actions to postpone patients starting on dialysis; this would imply important savings for the healthcare systemThe greater the severity of CKD, the higher the costs of patients with CKD. The more patients are kept at the initial stages, the higher the savings will be for the healthcare system.Early management of patients with CKD in the predialysis stages, as well as the use of proper preventive treatments, may in fact slow the progression of kidney damage, including access to dialysis, with consequent savings of economic resources

Background {#Sec1}
==========

Chronic kidney disease (CKD) is an important public health problem. In the US, CKD is the ninth leading cause of death and affects more than 10% of the adult population. Total US Medicare expenditure for CKD (excluding drugs) accounts for 6% of all Medicare costs \[[@CR1]\].

The literature relating to costs of CKD include different contributions for end-stage renal disease (ESRD) that requires renal replacement therapy (RRT) in the form of dialysis or transplantation. These costs represent 2--3% of the annual healthcare budget of public health systems \[[@CR2]\]. The annual growth rate of dialysis costs has ranged from 6 through 12% over the past 2 decades in most developed countries \[[@CR3]\]. In Italy in 2001, it was estimated that 1.8% of the total healthcare budget was spent on ESRD patients, representing 0.083% of the general population \[[@CR4]\]. According to more recent estimates, total healthcare spending on ESRD has reached €2.1 billion in 2010 (i.e. 1.9% of the healthcare budget) and healthcare costs of patients receiving dialysis range from €29.8K to €43.8K depending on the techniques used (peritoneal dialysis vs. haemodialysis) \[[@CR5]\].

Costs in the earlier stage of CKD before dialysis are less investigated. A paper published in 2009 on US Medicare costs shows that the average cost per patient receiving dialysis is 2.5 times the costs of patients with CKD, and the average healthcare costs of patients with CKD is three times the unit cost of patients covered by Medicare \[[@CR6]\]. More recent research on the cost of CKD in Australia, relying on a national longitudinal population-based study of Australian adults with diabetes aged ≥ 25 years, shows a significant difference in the per-person annual direct healthcare costs by CKD status---from \$1829 for those without CKD to \$14,545 for those with stage 4 or 5 CKD, where stages refer to decreasing glomerular filtration rate (GFR) and range from 1 to 5 \[[@CR7]\].

Another retrospective study on the population with type 2 diabetes was carried out in Germany. The costs for patients in stages 4 and 5 were 1.97 and 3.5 times, respectively, the costs of patients in stage 3 \[[@CR8]\]. In Italy, the evidence on predialysis costs is also limited. A recent study carried out in Tuscany (6.2% of the Italian population) in 2012 and 2013, and focusing on stage 4 and 5 CKD, produced estimated direct medical costs of €4352, i.e. 44% of the overall social cost (€9855) \[[@CR9]\]. A retrospective analysis on prescriptions by 124 general practitioners (GPs) for 12,400 patients has estimated 2010 mean healthcare costs per patient ranging from €450 in stages 1--2, to €3292 in stage 5 \[[@CR5]\]. More recent retrospective studies have been carried out on regional databases and have investigated the unit cost per patient in the predialysis and dialysis phases. The first study, in the Piedmont region (7.2% of the Italian population), compared incident-to-dialysis patients observed for the 12 months before dialysis entrance (€11,123) and established dialysis patients (€53,764) \[[@CR10]\]. The second analysis was carried out in the Lombardy Region (16.5% of the Italian population) and found a unit healthcare cost per patient of €5239, €12,303 and €38,821 in the 12- to 24-month period before dialysis, 0--12-month period before dialysis, and the first year of dialysis, respectively \[[@CR11]\].

However, none of these studies investigated the healthcare costs of patients with CKD, using a prospective approach and relying on data from specialist centres, which may provide a more complete collection of healthcare resources used than GPs.

Research Question and Methods {#Sec2}
=============================

This research aims at filling the gap in the literature, i.e. estimating the annual costs of patients with CKD not receiving dialysis treatment, using the Italian healthcare system perspective and relying on a prospective multicentre approach. The costs of patients with CKD includes the costs of CKD and the costs of comorbidities that are possible consequences of CKD, but not the costs of comorbidities not linked to the disease.

Patients aged \> 18 years with CKD (as defined based on the Kidney Disease Outcomes Quality Initiative (K-DOQI) guidelines \[[@CR12]\]) in the predialysis phase were included in the study. Patients with comorbidities with a life expectancy of \< 1 year (e.g. advanced-phase malignancies, advanced liver disease), patients enrolled in a clinical trial (interventional study) receiving erythropoietin, vitamin D or phosphate binders at the start of the survey, and renal transplant recipients were not included in the study. Dropouts included patients who had started dialysis or died during the follow-up period, who had withdrawn consent, and who had been lost to follow-up.

Data on resource consumption were collected through an electronic case record form (e-CRF). Patients were recruited in 24 centres (originally 26, but in one centre the follow-up of all patients was interrupted for organisational issues, and one centre did not enrol any subjects) in 15 of the 21 Italian healthcare regions. Participating centres were selected according to the following criteria: (1) specialisation in nephrology; and (2) more than 20 patients visited the centre per week. Patients were consecutively recruited in order to limit selection bias. Sample size was determined on the grounds of alleged secondary hyperparathyroidism outcome in stage 4 patients since no other epidemiologic data had been reported in the literature at the time of the study design.

The follow-up lasted 3 years. For all participants, defined as those patients who met the inclusion/exclusion criteria after signing the informed consent, clinical and healthcare consumption data were recorded. The recruitment phase started on December 2010 and finished in September 2011. The follow-up phase was terminated in September 2014.

The study was also designed to collect data on productivity loss; however, despite 321 patients (36.4%) being 25--65 years of age, working loss days were collected for nine patients only. Hence, productivity-loss data were not included in the analysis.

The physician responsible filled in the form every 6 months, up to 36 months. Responders were asked to collect data on (1) molecules, daily dosage, and treatment days; (2) outpatient services, including visits, diagnostic procedures and laboratory tests; and (3) inpatient services and the relevant Diagnosis-Related Group (DRG) code.

Drug unit costs were calculated as a 2014 mean unit price per dose (Drugs National Formulary), considering different products per molecule (the e-CRF did not allow responders to quote the brand name of the prescribed product) and different possible distribution systems. In fact, some drugs (e.g. new antidiabetic drugs or epoetins) may be distributed as follows.By community pharmacies (ordinary distribution): list price (net of discounts and co-payment) is paid by the Italian National Health Service (NHS).Directly by health authorities: ex-factory price, net of local discounts, is paid by the NHS. Local discounts were not available and gross ex-factory price was used.By community pharmacies on behalf of health authorities: ex-factory price, net of local discounts is paid by the NHS; pharmacies also receive a remuneration, as defined by local agreements. Since many responders did not distinguish between distribution by health authorities and distribution by community pharmacies on behalf of health authorities, we did not include the remuneration paid to pharmacies; local discounts were not available and gross ex-factory price was used.

For ordinarily distributed molecules with at least one generic available, we used the minimum price per dose since the NHS reimburses this cost.

Estimates of unit costs of ordinary and same-day (day-hospital) hospitalisations relied on the relevant 2012 national fee-for-service \[[@CR13]\]. Extra fees per day of stay over the thresholds (maximum length of stay per DRG) were considered. Outpatient services were also monetized using the national fee-for-service \[[@CR13]\].

If the patient's follow-up lasted over 3 years (the actual follow-up period could have been longer than 36 months if the time interval between two visits was longer than 6 months) or less than 3 years but more than 1 year (some patients dropped out), the annual cost per patient was estimated as 'daily cost × 365'. However, if the patient's follow-up lasted less than 1 year (patients dropped-out), the annual cost was estimated as 'daily cost × follow-up days'.

We performed descriptive statistics on unit costs per patient according to (1) patients' status, i.e. completed follow-up or dropout; (2) starting-level disease severity, measured through the GFR, ranging from 1 (lower CKD stage) to 5 (higher CKD stage); (3) sex and age of patients---10 age-group intervals were considered (18--24, 25--34, 35--44, 45--54, 55--64, 65--74, 70--74, 75--79, 80--84, over 84 years); (4) geographical areas (northern region, including Piedmont and Aosta Valley, Liguria, Lombardy, Veneto, Friuli Venezia Giulia; central region, including Tuscany, Marche, Latium, Abruzzo and Molise[1](#Fn1){ref-type="fn"}; and southern region, including Campania, Apulia and Basilicata, and Sardinia; (5) presence of comorbidities (hypertension/diabetes/dyslipidaemia were the most frequent); and (6) proteinuria at the date of recruitment. Statistical significance of differences between values was tested using the Kruskal--Wallis test.

The regression was performed using a linear model ordinary last squares (OLS) with robust standard error estimation to allow heteroskedasticity in residuals. The explanatory variables were geographical area (north, centre, south), age-group class, sex, set of comorbidities (also interacted with one another), severity at enrolment, presence of proteinuria at enrolment, and total time of enrolment.

Results {#Sec3}
=======

Healthcare cost analysis was performed on 864 patients, i.e. 884 patients recruited, net of 16 patients from one centre that had not completed follow-up and 4 patients whose costs were not filled in on the e-CRF. Overall, 586 patients completed the follow-up, whereas 278 patients interrupted the study before the last visit (32.2%; ranging from 51.4% in Veneto and 18% in Apulia and Basilicata) (Table [1](#Tab1){ref-type="table"}). Among the dropouts, 36.0% of patients began dialysis treatment, 34.5% were lost to follow-up and 25.2% died. The study population mainly consisted of males (59.7%), and patients over 65 years of age accounted for 63.2% of the study population (18.6% were over 80 years of age); mean age was 66.3 years (± 14.6 years). At the time of enrolment, mean time from diagnosis was 7.0 years (± 7.9 years) and only 0.7% of patients were at their first nephrologist visit (data not reported in Table [1](#Tab1){ref-type="table"}). Patients with a starting GFR level in stages 1, 2, 3, 4 and 5 totalled 68, 156, 355 (167 in stage 3a and 188 in stage 3b), 206, and 79, respectively. Hypertension, hypercholesterolemia and diabetes were the most frequent comorbidities, with 89.1% of patients experiencing at least one of these comorbidities and 107 patients (12.4%) being affected by all three.Table 1Characteristics of the recruited patientsVariable*n* (total = 864)%Variable*N* (total = 864)%*Follow*-*up completed vs. dropoutAge groups, years*Follow-up completed58667.818--2470.8Dropout27832.225--34252.9 Death708.135--44606.9 Dialysis10011.645--54778.9 Lost to follow-up9611.155--6414917.2 Consent withdrawal70.865--6910712.4Inclusion criteria not satisfied30.370--7414216.4Others20.275--7914516.880--8411012.7\> 84424.9*Region*Northern region38444.4 Piedmont and Aosta Valley859.8*Starting CKD stage* Liguria647.41687.9 Lombardy16519.1215618.1 Veneto354.1335541.1 Friuli VG354.13a16719.3Central region27932.33b18821.8 Tuscany9811.3420623.8 Marche404.65799.1 Latium10111.7 Abruzzo and Molise404.6*Comorbidity*Southern region20123.3None9410.9 Campania455.2Diabetes172.0 Apulia and Basilicata617.1Dyslipidaemia424.9 Sardinia9511.0Hypertension27531.8Diabetes + dyslipidaemia172.0*Sex*Diabetes + hypertension10912.6Female34840.3Dyslipidaemia + hypertension20323.5Male51659.7Diabetes + dyslipidaemia + hypertension10712.4*Starting proteinuria*Yes39645.8No36542.2Unkown10311.9*CKD* chronic kidney disease

Mean annual total (healthcare) cost per patient equalled €2723 (Fig. [1](#Fig1){ref-type="fig"}). All differences between values (status of patients, age, disease progression, comorbidities, starting GFR level, proteinuria at recruitment, and region) were found to be statistically significant according to the Kruskal--Wallis test, apart from the difference in unit costs between the male and female populations.Fig. 1Mean annual total cost per patient (€). *DO* dropouts, *CV* coefficient of variation. \*12 dropouts for reasons other than death, dialysis, and lost to follow-up

The unit costs of patients who dropped out were almost double those of patients who completed the follow-up. Dropped-out patients starting dialysis and dead patients during the follow-up period showed the highest mean annual cost, confirming that proximity to dialysis and death raises costs.

Disease progression produces an increase in costs. The higher the starting CKD stage, the higher the healthcare cost per patient. The largest difference between unit costs was found when comparing stage 3b patients with stage 3a patients (+ 56%) and stage 4 patients with stage 3b patients (+ 62%) (Table [2](#Tab2){ref-type="table"}). Stage 3 accounted for more than 40% of patients.Table 2Mean annual cost per patient according to their status (starting CKD level, proteinuria, comorbidities, geographic area) (€)*N*MeanMedianSDCoefficient of variation (%)SE95% CI*Starting CKD stage*CKD 16811698651246107151.1867.51470.8CKD 215615068741845123147.71214.01797.7CKD 3355212210742621124139.11848.52395.6 CKD 3a167163510191800110139.31359.91910.0 CKD 3b188255510843119122227.52106.13003.5CKD 4206414723255554134387.03384.14910.0CKD 57954533859529397595.54267.06638.2*Proteinuria at recruitment*Yes396293715263781129190.02563.63310.7No365210010452865136150.01805.22395.1Unknown103410818406348155625.52867.45348.6*Comorbidities*Diabetes1714728401576107382.3661.92282.7Dyslipidaemia42184512282003109309.01220.72468.8Hypertension275267510234197157253.12176.43172.8Diabetes + dyslipidaemia1722332014171277415.31353.03113.9Diabetes + hypertension109308316623230105309.42469.43695.9Hypertension + dyslipidaemia203268214063200119224.62239.53125.1Diabetes + dyslipidaemia + hypertension107386520384998129483.22906.94822.7*Regions*Northern384283612374285151225.21964.52851.0Central279240811553761156218.72405.73265.7Southern201294616813236110228.32495.83396.0*CKD* chronic kidney disease, *SD* standard deviation, *SE* standard error, *CI* confidence interval

Proteinuria also seems an important explanatory variable of annual cost per patient. Costs for patients without a proteinuria at the recruiting date were 25% less than healthcare costs for patients with proteinuria (Table [2](#Tab2){ref-type="table"}).

Patients with CKD often have other diseases, with diabetes, dyslipidaemia and hypertension being the most important and frequent. Hypertension seems to have a larger impact on unit costs; patients in whom renal failure is associated with hypertension alone and hypertension with diabetes show higher costs. However, not all comorbidities have an important effect on costs, e.g. unit costs of patients with diabetes are lower than the average unit cost (Table [2](#Tab2){ref-type="table"}).

Mean annual cost per patient shows important variations across regions. On average, the cost per patient is higher in the southern and northern regions than in the central region (Table [2](#Tab2){ref-type="table"}), despite the proportion of dropped out patients (who are, on average, costlier) being very similar across all areas.

Ageing produces a rise in costs (Fig. [2](#Fig2){ref-type="fig"}), however the growing trend shows an inflection point in the 70--74 age group. Costs are higher for males (€2779), but the difference in the female population is negligible (+3%).Fig. 2Mean annual cost per patient according to the different age groups (years) (€)

Pharmaceuticals, hospitalisation, and outpatients services account for 71.5, 18.8 and 9.7% of total healthcare expenditure, respectively (Table [3](#Tab3){ref-type="table"}); hence, pharmaceuticals are the most important component of healthcare expenditure. Erythropoietins are the major component of drug expenditure (accounting for 36.4% of total drug expenditure), followed by antihypertensive drugs (18.7%) and drugs for CKD \[12.1%, including vitamin D (9.6%) and chelating agents (2.5%)\].Table 3Mean annual cost per patient for drugs, and outpatient and inpatient services (€)Drugs (%)Outpatient (%)Inpatient (%)Total (%)*Patient status*All1946.8 (71.5)263.8 (9.7)512.5 (18.8)2723.1 (100.0)Follow-up completed1590.1 (76.0)259.6 (12.4)241.8 (11.6)2091.5 (100.0)Dropout2698.7 (66.6)272.5 (6.7)1083.2 (26.7)4054.5 (100.0)*Starting CKD stage*1813.2 (69.6)214.6 (18.4)141.4 (12.1)1169.2 (100.0)21096.7 (72.8)225.7 (15.0)183.4 (12.2)1505.8 (100.0)3a1196.7 (73.2)192.0 (11.7)246.3 (15.1)1634.9 (100.0)3b1790.1 (70.1)227.6 (8.9)537.0 (21.0)2554.8 (100.0)43048.7 (73.5)326.3 (7.9)772.0 (18.6)4147.0 (100.0)53686.4 (67.6)456.3 (8.4)1309.8 (24.0)5452.6 (100.0)*CKD* chronic kidney disease

The contribution of hospitalisation to total costs is higher for patients who dropped out than for patients who completed the follow-up. More advanced is the starting CKD stage, the higher the proportion of inpatient costs (from 12.1% of total costs in stage 1 to 24% in stage 5) (Table [3](#Tab3){ref-type="table"}).

Table [4](#Tab4){ref-type="table"} illustrates the results of the multiple regression model. The dependent variables are per capita total and annual drug expenditure. Explanatory variables are listed in column 1, while columns 2 and 3 include the reference variable and other variables, respectively. In columns 4 and 5, correlation coefficients for total healthcare and drug costs are reported. The explanatory power of the model is not particularly high (*R*-squared ranges from 0.136 to 0.165). However, coefficients are significant for some variables; a higher starting CKD stage, together with the presence of three comorbidities, dropout status, and belonging to the southern region are significantly correlated with both per capita healthcare and drug expenditure. These variables seem to explain more healthcare and drug expenditure than other variables (i.e. age, sex, and the presence of proteinuria at recruitment).Table 4Multiple regression analysis for total annual healthcare and drug costs per patientVariablesReference variableOther variable(s) Coefficient (healthcare costs per patient)Coefficient (drug costs per patient)12345Follow-up completed vs. dropoutDropoutFollow-up completed(1.463)\*\*(1.141)\*\*Follow-up days--Follow-up days11611789\*\*Geographical areaCentral regionNorthern region170.5102.5Southern region704.3\*\*722.7\*\*\*SexMaleFemale(393.0)(237.6)Age--Age11.7715.58ComorbidityNone31634\*\*1228\*\*2 (diabetes + hypertension)889.3392.31 (dibetes)432.0448.02 (dyslipidaemia + hypertension)462.6128.31 (dyslipidaemia)203.9234.11 (hypertension)499.8205.92 (diabetes + dyslipidaemia)322.5795.8CKD stage12217.4184.23a221.8224.73b1095\*\*\*828.3\*\*\*42501\*\*\*2027\*\*\*53606\*\*\*2742\*\*\*ProteinuriaUnknownYes(954.9)(1063)\*No(725.6)(1026)\*Constant744.561.01*N*864864*R*-squared0.1650.136*CKD* chronic kidney disease\*\*\* *p* \< 0.01, \*\* *p* \< 0.05, \* *p* \< 0.01

Discussion {#Sec4}
==========

The present study is the first analysis that has investigated the unit healthcare costs per patient with CKD before dialysis, using a national, observational, multicentre, prospective approach. The long follow-up period (3 years) and the involvement of healthcare centres in different regions allowed our analysis to produce a reasonable estimate of the actual unit cost in Italy, despite not stating that recruited patients represented all Italian patients with CKD before dialysis as no epidemiological data on CKD were available (incidence, prevalence, distribution of its various stages, etc.). However, the multicentric nature of the study and the fact that most regions were included, and recruited centres were selected on the grounds of a minimum number of patients who visited the centre, make this study more representative of the population than other studies focussed on a single region \[[@CR10], [@CR11]\].

Previous studies have investigated this topic using a retrospective approach applied to prescriptions by GPs, or single-region administrative databases. Despite the different approach, we found some commonalties with other studies, i.e. mean annual costs well below dialysis costs \[[@CR5], [@CR10], [@CR11]\] and an important increase in costs for more severe disease stages \[[@CR5]\].

The study has some limitations. Unit drug costs were estimated as a weighted average price of all products sharing the same molecule and formulation (prescriptions were recorded using the name of the molecule) in all possible distribution settings (ordinary distribution, direct distribution, distribution 'on behalf'). It would have been more appropriate to ask responders to complete the e-CRF using the brand name instead of the name of the molecule; however, responders preferred using the generic name of the molecule. For outpatient and inpatient services, national fees were used as a proxy of unit costs because unit costs per patient were not available; however, fees do not necessarily coincide with unit (full) costs, even if, in principle, the Ministry of Health determined fees on the grounds of cost estimates \[[@CR10]\]. Furthermore, some responders were rather imprecise in compiling the e-CRF. In many cases, they quoted the wrong DRG number or compiled a wrong drug dose. After consultation with the responder, their records were eventually changed. The use of an e-CRF may have led to recall bias for those data orally reported by patients, i.e. hospitalisations and lost work days. The former were further checked with the physicians, while the latter were not used in the analysis. Recall bias is possibly one of the drivers of important differences in cost breakdowns. In our analysis, inpatient costs accounted for 18.6--24% of total healthcare costs in the advanced stages (rising to more than 26% for patients who dropped out). Another study, which relied on a regional administrative database, has reported an incidence of hospitalisation costs higher than 75% in the 12 months preceding dialysis entrance for incident-to-dialysis patients \[[@CR10]\].

Conclusions {#Sec5}
===========

Despite these limitations, this analysis has important policy implications. First, the annual healthcare costs per patient are approximately 10% of the healthcare costs of patients receiving dialysis \[[@CR5]\]. If the social perspective was adopted, the difference could be even higher, considering working days lost and informal care for patients receiving dialysis. Hence, managing patients with CKD in order to avoid dialysis should be a priority to better allocate scarce resources. Second, one of the most important explanatory variables of CKD cost variations is CKD stage---the higher the CKD stage, the higher the unit cost per patient. Unit costs rocket when patients move from stage 3a to stage 3b and from stage 3b to stage 4. An increased effort should be made to maintain patients at levels 3a and 3b in order to avoid cost escalations in the future.

Drugs represent the main component of CKD healthcare costs. Considering that (1) they avoid future costs and (2) drug unit costs also include pharmaceuticals for comorbidities (hypercholesterolemia, diabetes and dyslipidaemia), prevention of dialysis through an appropriate management of drug therapy seems a value-for-money investment.

Some variations in costs have been found across regions; however, differences across areas are not as huge as differences across CKD stages. Furthermore, geographical area was one of the most important explanatory variables. This aspect has not been further investigated, but it is likely that drug prescriptions should be better managed. In the southern region where healthcare unit costs are higher, the incidence of drugs on total healthcare expenditure is higher. Investment in drugs provides value for money, but drugs should be appropriately managed to avoid wasting resources.

In brief, this prospective observational study has provided important data to policy makers. Avoiding progression towards severe CKD and dialysis, together with a more appropriate drug prescription, would imply thousands of Euros saved, together with benefits to patients and society as a whole.

Abruzzo and Molise are usually considered southern regions but we preferred to include them in the central region group because they are more similar to that group.
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